Clinical Trials Browser

OTHER × Endometrial Neoplasms × pembrolizumab × Clear all

NCT03835819 2026-06-01

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Phase 2 Active not recruiting

18 enrolled 17 charts

Endometrial Neoplasms

NCT05761951 2026-05-19

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT07594015 2026-05-18

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

Phase 2 Recruiting

Endometrial Neoplasms

NCT03932409 2026-05-08

FIERCE

Phase 1 Active not recruiting

Endometrial Neoplasms

NCT06180733 2026-05-01

PAM-II

Phase 2 Active not recruiting

GynecologicLymphoid

Lymphoma, Follicular, Uterine Neoplasms, Endometrial Neoplasms

NCT05036681 2026-03-27

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Phase 2 Terminated

9 enrolled 10 charts

Neoplasm Metastasis, Endometrial Neoplasms

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05603910 2026-02-24

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Phase 1 Recruiting

Endometrial Neoplasms

NCT04781088 2026-02-11

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

Phase 2 Recruiting

Endometrial Neoplasms

NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Phase 2 Terminated

4 enrolled 8 charts

Recurrence, Endometrial Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02899793 2025-06-11

Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

Phase 2 Completed

25 enrolled 15 charts

Endometrial Neoplasms

NCT06502743 2025-04-03

PENELOPE

Phase 2 Recruiting

Endometrial Neoplasms

NCT02630823 2025-01-03

MK-3475 Immunotherapy in Endometrial Carcinoma

Phase 1 Completed

10 enrolled 9 charts

Endometrial Neoplasms

NCT06549855 2024-08-12

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Phase NA Not yet recruiting

Turcot syndrome, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT02728830 2024-02-21

A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

Phase EARLY_PHASE1 Completed

39 enrolled 16 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Endometrial Neoplasms

NCT03694834 2023-11-28

Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer

Phase EARLY_PHASE1 Terminated

Uterine Neoplasms, Endometrial Neoplasms

NCT05419817 2023-02-27

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Phase 2 Withdrawn

Endometrial Neoplasms

NCT04014530 2023-02-01

ATAPEMBRO

Phase 1/2 Recruiting

GastrointestinalGynecologic

Neoplasm Metastasis, Colorectal Neoplasms, Endometrial Neoplasms

NCT02549209 2022-03-02

Pembro/Carbo/Taxol in Endometrial Cancer

Phase 2 Completed

46 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT04611139 2022-03-02

Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers

Phase 1 Withdrawn

Endometrial Neoplasms

NCT03276013 2021-10-05

TOPIC

Phase 2 Completed

Neoplasms, Endometrial Neoplasms

NCT03192059 2021-09-08

PRIMMO

Phase 2 Completed

Uterine Cervical Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

NCT04197219 2020-11-05

Pembrolizumab With Axitinib in Recurrent Endometrial Cancer

Phase 2 Withdrawn

Endometrial Neoplasms